Prostate cancer-related prostate hyperplasia (PCPH) is an enlargement of the prostate gland. It is caused by a buildup of abnormal cells in the prostate. This can cause the prostate to become larger and put pressure on the bladder and urethra. This can make it difficult to urinate.
The main symptom of PCPH is difficulty urinating. This can include a weak or slow stream, frequent urination, and the need to strain to urinate. Other symptoms include pain in the lower abdomen, pelvic area, or back, and blood in the urine.
The exact cause of PCPH is unknown, but certain dietary and lifestyle factors may increase the risk. These include a diet high in fat and processed foods, alcohol consumption, smoking, and being overweight or obese.
Making healthy lifestyle changes can help reduce the risk of PCPH. Eating a diet rich in fruits, vegetables, whole grains, and lean proteins can help maintain a healthy weight. Limiting alcohol consumption and avoiding smoking can also help. Regular exercise can also help reduce the risk.
What percentage of the population suffer from Prostate Cancer-Related Prostate Hyperplasia?
It is estimated that about 10-15% of men over the age of 50 suffer from PCPH. The risk increases with age, and it is more common in African-American men. It is important to talk to your doctor if you have symptoms of PCPH, as early diagnosis and treatment can help reduce the risk of complications.
Fasting has been shown to reduce the symptoms of Prostate Cancer-Related Prostate Hyperplasia (PCRPH) by reducing inflammation and oxidative stress. This is due to the body being able to use its own energy reserves to repair and maintain cells, while also reducing the amount of hormones and other substances that can cause inflammation in the prostate. Fasting also reduces the amount of circulating insulin and other hormones that can cause prostate enlargement. In addition, fasting can help to reduce the risk of prostate cancer by reducing the amount of circulating androgens, which are known to be involved in the development and progression of prostate cancer.